Novo Nordisk A/S (NYSE:NVO) Receives $126.25 Consensus PT from Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $133.60.

Several equities analysts have recently commented on the stock. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Monday, April 1st. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a report on Friday. They set an “outperform” rating and a $163.00 price target on the stock. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective on the stock.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently modified their holdings of the company. Roundview Capital LLC lifted its position in shares of Novo Nordisk A/S by 0.6% during the first quarter. Roundview Capital LLC now owns 18,803 shares of the company’s stock worth $2,088,000 after purchasing an additional 106 shares in the last quarter. BlackRock Inc. raised its holdings in Novo Nordisk A/S by 45.4% during the first quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock worth $559,235,000 after purchasing an additional 1,571,747 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Novo Nordisk A/S by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 739,585 shares of the company’s stock worth $82,131,000 after purchasing an additional 6,903 shares in the last quarter. Blair William & Co. IL grew its position in shares of Novo Nordisk A/S by 12.7% during the first quarter. Blair William & Co. IL now owns 19,466 shares of the company’s stock worth $2,136,000 after acquiring an additional 2,194 shares during the last quarter. Finally, Sei Investments Co. grew its position in shares of Novo Nordisk A/S by 17.5% during the first quarter. Sei Investments Co. now owns 107,175 shares of the company’s stock worth $11,913,000 after acquiring an additional 15,996 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.7 %

NYSE:NVO opened at $124.52 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The firm has a market cap of $558.79 billion, a price-to-earnings ratio of 46.12, a price-to-earnings-growth ratio of 2.08 and a beta of 0.41. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The firm has a 50-day moving average price of $125.93 and a two-hundred day moving average price of $109.61.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, equities analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio is currently 48.89%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.